Publication: Drug Design, Development and Therapy
Abstract
Nalbuphine is an opioid used during general anesthesia, but its pharmacokinetics in patients with impaired liver function had not been well characterized. This study compared nalbuphine pharmacokinetics following a single intravenous dose in 24 surgical patients with normal, mild, or moderate/severe liver dysfunction, using non-compartmental analysis in Phoenix WinNonlin. Patients with moderate/severe liver dysfunction showed an approximately 33% longer elimination half-life and 85% larger volume of distribution compared with those with normal liver function, with weight, platelet count, and total bilirubin identified as significant covariates. These findings suggest nalbuphine should be used with caution in patients with moderate or severe liver dysfunction undergoing general anesthesia.
Author(s): Gao XN, Nie XY, Gao JL, Heng TF, Zhang YQ, Hua L, Sun YQ, Feng ZY, Wang MX, Jia L
Published: July 26, 2022
Phoenix WinNonlin: PK Across Liver Function
Phoenix WinNonlin’s non-compartmental analysis showed meaningfully longer half-life and larger volume of distribution with worsening liver function in this nalbuphine study. As part of a Phoenix platform accessible from any browser, on any device, Phoenix NLME can be paired with Modeling Assistant, an AI copilot for model building and PML authoring.
